Glycoprotein platelet inhibitors prevent platelet adhesion by binding to the glycoprotein IIb/IIIa receptors on the plasma membrane of platelets. They stop the actual substrates of the glycoprotein receptors from binding to the receptor, so inhibit platelets from sticking together to form a thrombus, which can lead to stroke, myocardial infarction or deep vein thrombosis.
Glycoprotein platelet inhibitors are used in patients with angina, after a heart attack, angioplasty or other types of coronary vasculature procedures.
Name | Updated |
---|---|
Eptifibatide (Eptifibatide [ ep-ti-fye-ba-tide ]) | 16-Aug-2023 |
Tirofiban (Tirofiban [ tye-roe-fye-ban ]) | 16-Aug-2023 |
Reopro (Abciximab (systemic)) | 14-Jul-2023 |
Integrilin (Eptifibatide [ ep-ti-fye-ba-tide ]) | 13-Jul-2023 |